Neupogen (Filgrastim)

Filgrastim binds to the G‑CSF receptor on hematopoietic stem and progenitor cells in the bone marrow. This binding triggers intracellular signaling that promotes the proliferation, differentiation and activation of neutrophil precursors, leading to a rapid rise in circulating neutrophils.

The dose of Neupogen is individualized and set by the treating physician based on the patient’s clinical condition, body weight, and the specific indication. Healthcare professionals determine the appropriate amount, frequency and duration of therapy.

Data on the use of filgrastim in pregnancy and lactation are limited. It should only be used when the potential benefit to the mother outweighs any possible risk to the fetus or infant, and decisions should be made in consultation with an obstetric specialist.

To place an order, submit an enquiry on the Neupogen product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and any necessary import documentation.

The primary alternative to filgrastim is pegfilgrastim, a long‑acting pegylated form that requires fewer injections. Both agents belong to the G‑CSF class and increase neutrophil counts, but pegfilgrastim provides a prolonged effect, whereas filgrastim allows more flexible dosing and may be preferred when rapid titration is needed.

Neupogen must be stored refrigerated at 2‑8 °C (36‑46 °F). It should be kept in its original container, protected from light, and must not be frozen or shaken. If the product reaches room temperature, it may be used for a limited period as indicated in the product’s labeling.

Neupogen is given as a subcutaneous injection, typically into the abdomen, thigh or upper arm. The injection site should be rotated to reduce local reactions, and aseptic technique must be followed. Administration is performed by a qualified healthcare professional or a trained patient under medical supervision.

Serious adverse events include splenic rupture, acute respiratory distress syndrome (ARDS), severe allergic reactions such as anaphylaxis, and extreme leukocytosis that can lead to vascular complications. Patients should be monitored for abdominal pain, respiratory difficulty, rash or swelling, and any sudden changes in blood counts.

Neupogen is contraindicated in patients with known hypersensitivity to filgrastim or any of its excipients. Caution is advised for individuals with a history of splenic disorders, uncontrolled infections, or severe renal impairment, and it should be avoided in pregnant or nursing women unless clearly indicated by a physician.